RESEARCH MONOGRAPH · KDC-MN-232
Clozapine
Clozapine (Clozaril) is the most effective antipsychotic ever developed, and it has held that title since the 1980s without serious challenger. It was approved by the FDA in 1989 specifically for treatment-resistant schizophrenia and remains the only drug demonstrated to reduce suicidality in schizophrenia. The catch is severe: roughly one in 100 patients develops agranulocytosis, a potentially fatal collapse of white blood cell production, which is why every patient on clozapine in the United States must submit to weekly, then biweekly, then monthly blood draws indefinitely. Mechanistically it is the prototype atypical antipsychotic, with weak D2 blockade compensated by potent 5-HT2A blockade and a wide net of effects on histamine, muscarinic, and adrenergic receptors. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Atypical antipsychotic / D4-D2 multireceptor antagonist
The prototype atypical antipsychotic; the gold standard for treatment-resistant schizophrenia, limited by agranulocytosis risk requiring weekly blood monitoring.
Abstract
Clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CAS 5786-21-0; molecular formula C18H19ClN4; molecular weight 326.82) is a dibenzodiazepine atypical antipsychotic developed at Wander/Sandoz and approved by the FDA in 1989 under the trade name Clozaril. The compound is the prototype atypical antipsychotic, introducing the receptor profile that defines the class: weak D2 antagonism (Ki approximately 130 nM) combined with potent 5-HT2A antagonism (Ki approximately 16 nM), producing antipsychotic efficacy without the extrapyramidal symptoms typical of high-affinity D2 antagonists. Off-target activity is broad: H1, alpha-1, muscarinic M1-M5 (Ki approximately 7 nM at M1), 5-HT2C, 5-HT3, 5-HT6, 5-HT7 antagonism, contributing to sedation, weight gain, sialorrhea (paradoxical from M4 partial agonism), and orthostatic hypotension. The defining clinical feature is efficacy in treatment-resistant schizophrenia, where clozapine consistently outperforms other antipsychotics; the limitation is approximately 1 percent agranulocytosis incidence, requiring weekly CBC monitoring through the first 6 months and biweekly thereafter. Plasma half-life is 12 hours; metabolism is via CYP1A2 (primary), CYP3A4, CYP2D6. Used as the canonical atypical antipsychotic in mechanism studies and as the gold standard for treatment-resistant schizophrenia.
Mechanism of action
Weak D2 antagonism, potent 5-HT2A antagonism, broad off-target activity (H1, alpha-1, muscarinic, 5-HT2C/3/6/7). Defines the atypical antipsychotic profile.
Reported research dose ranges
Clinical 100 to 900 mg per oral administration daily, slowly titrated. Rodent studies 1 to 30 mg/kg/day.
References
- Kane J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988.
- Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999.
- Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998.
Read the full monograph
The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.